Personalis received UK Conformity Assessed (UKCA) marking for its NeXT Personal Dx minimal residual disease test, enabling clinical use across England, Wales, and Scotland. The company partnered with Link Medical Solutions to expand commercialization across Great Britain. The NeXT Personal MRD assay is designed to detect trace circulating tumor DNA for recurrence monitoring and therapy response tracking, and it recently added U.S. Medicare coverage for pre-surgical monitoring in breast cancer. Personalis said UKCA approval supports its strategy to streamline companion diagnostic planning with biopharma partners. For diagnostics and precision oncology, this is a practical regulatory footprint expansion—lowering friction for MRD-linked clinical development and potentially broadening patient access to MRD-driven decision-making in routine care pathways.